YZi Labs criticizes CEA Industries’ poison pill in deepening boardroom conflict

YZi Labs, an investment firm backed by Changpeng Zhao, has strongly criticized Nasdaq-listed CEA Industries for implementing a "poison pill" stockholder rights plan and amending bylaws. YZi Labs argues these measures are "stockholder-unfriendly" and designed to prevent shareholders from exercising control via written consent, escalating a conflict that began after a major partnership five months prior.

The conflict intensified when YZi Labs sought board control through filings aimed at expanding the board and installing its own directors. YZi Labs claims CEA has underperformed since a $500 million private placement, despite significant gains in its core treasury asset, BNB. The "poison pill" triggers dilution if any party acquires 15% or more of shares without board approval.

YZi Labs also expressed concern over comments by CEA CEO David Namdar suggesting a potential switch from BNB to other crypto assets like Solana. YZi Labs stated it remains committed to constructive dialogue to protect shareholder interests and the integrity of the BNB ecosystem.

(Source：The Block)